Desuden blev det præciseret i produktresuméet, at dosisoptrapninger kun må ske efter en klinisk vurdering, og at den laveste effektive dosis skal opretholdes af hensyn til risikoen for dosisrelaterede bivirkninger.
Additionally, it was clarified in the SPC that dose increments should only be made after a clinical evaluation and that the lowest effective dose should be maintained, given the risk of dose-related adverse effects.